Good evening :)
Place Order
Add to Watchlist

Orchid Pharma Ltd

ORCHPHARMA

Orchid Pharma Ltd

ORCHPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,512 cr, stock is ranked 694
High RiskStock is 3.99x as volatile as Nifty
1,331.355.86% (+73.65)
1,331.355.86% (+73.65)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,512 cr, stock is ranked 694
High RiskStock is 3.99x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,512 cr, stock is ranked 694
High RiskStock is 3.99x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
58.375.57—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.226.550.48%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 0.78%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.37% to 0.23%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.83%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue898.35823.83703.29817.84508.08465.27627.03724.54850.23917.76
Raw Materialssubtract407.53373.85342.63263.14221.68245.60340.62406.10528.35760.73
Power & Fuel Costsubtract55.2854.3350.6948.7647.4439.3152.7461.2662.92
Employee Costsubtract86.8179.4186.2282.2874.8667.1163.2865.3569.64
Selling & Administrative Expensessubtract90.77104.8081.4055.1963.8236.6341.9234.9653.17
Operating & Other expensessubtract114.80267.3997.74162.43107.1932.046.4220.71-5.77
Depreciation/Amortizationsubtract145.27141.05133.31129.94117.93108.9287.0254.7933.2433.97
Interest & Other Itemssubtract294.24346.77310.266.696.2352.2133.4632.9016.7414.31
Taxes & Other Itemssubtract-17.25-48.34-46.190.000.000.003.522.15-0.22-2.82
EPS-32.04-55.69-39.657.80-20.20-28.55-0.4811.3520.1422.00
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Jun 16PDF
FY 2022

Annual report

PDF

Investor Presentation

Jun 20PDF
Dec 23PDF
Nov 23PDF
FY 2023

Annual report

PDF

Investor Presentation

May 11PDF
Feb 17PDF
Nov 18PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 14PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Orchid Pharma Ltd70.675.57—
Sun Pharmaceutical Industries Ltd47.866.830.71%
Cipla Ltd31.814.890.80%
Torrent Pharmaceuticals Ltd70.9717.150.81%

Price Comparison

Compare ORCHPHARMA with any stock or ETF
Compare ORCHPHARMA with any stock or ETF
ORCHPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.84%16.91%2.02%1.42%9.81%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun2.45%9.78%9.76%10.40%15.18%16.91%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.74%

Top 5 Mutual Funds holding Orchid Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
6.9756%1.78%0.06%31/110 (-15)
Invesco India Contra Fund - Growth - Direct Plan

Growth
3.1272%1.14%0.20%56/79 (-2)
Nippon India Pharma Fund - Growth - Direct Plan

Growth
1.4550%1.10%-0.02%27/36 (-2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ORCHPHARMA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Orchid Pharma consolidated net profit rises 212.23% in the June 2024 quarter

Net profit of Orchid Pharma rose 212.23% to Rs 29.35 crore in the quarter ended June 2024 as against Rs 9.40 crore during the previous quarter ended June 2023. Sales rose 33.62% to Rs 244.41 crore in the quarter ended June 2024 as against Rs 182.92 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales244.41182.92 34 OPM %13.2912.10 - PBDT36.5618.48 98 PBT28.1210.78 161 NP29.359.40 212 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Orchid Pharma announces board meeting date

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Orchid Pharma to conduct AGM

Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held on 12 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Road Ahead For Orchid Pharma & Cipla's Partnership To Combat UTI I MD Manish Dhanuka Shares Outlook
3 months agoNDTV Profit

Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India

3 months agoBusiness Standard

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

3 months agoBusiness Standard

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

3 months agoBusiness Standard

Orchid Pharma join hands with Cipla to launch new antibiotic in India

3 months agoBusiness Standard

Orchid Pharma - Enmetazobactam, First Indian NCE Gets U.S. FDA Nod: Systematix

7 months agoBloomberg Quint

Orchid Pharma - A Preferred Play On Import Substitution Opportunity: Systematix Initiates Coverage With A Buy

8 months agoBloomberg Quint